Literature DB >> 18467627

Effects of MEK5/ERK5 association on small ubiquitin-related modification of ERK5: implications for diabetic ventricular dysfunction after myocardial infarction.

Tetsuro Shishido1, Chang-Hoon Woo, Bo Ding, Carolyn McClain, Carlos A Molina, Chen Yan, Jay Yang, Jun-Ichi Abe.   

Abstract

Diabetes mellitus (DM) contributes to the exacerbation of left ventricle (LV) dysfunction after myocardial infarction (MI). Activation of ERK5, an atypical mitogen activated protein kinase with transcriptional activity, inhibits apoptosis and LV dysfunction after doxorubicin treatment. SUMOylation has been proposed as a negative regulator of various transcription factors. In the current study, we investigated the role of ERK5-SUMOylation in ERK5 transcriptional activity as well as on DM-mediated exacerbation of LV dysfunction and apoptosis after MI. ERK5 wild-type transcriptional activity was inhibited by Ubc9 (SUMO E2 conjugase) or PIAS1 (E3 ligase), but not in the ERK5-SUMOylation-site defective mutant (K6R/K22R). H2O2 and high glucose, 2 well-known mediators of diabetes, induced ERK5-SUMOylation, and the K6R/K22R mutant, dominant negative form of Ubc9, and siRNA-PIAS1 reversed H2O2-mediated reduction of ERK5 transcriptional activity in cardiomyocytes, indicating the presence of SUMOylation-dependent ERK5 transcriptional repression. Constitutively active form of MEK5alpha (CA-MEK5alpha) inhibited ERK5-SUMOylation independent of kinase activity, but dependent on MEK5-ERK5 association. To investigate the pathological role of ERK5-SUMOylation in DM mice after MI, we used cardiac specific CA-MEK5alpha transgenic mice (CA-MEK5alpha-Tg). MI was induced in streptozotocin (STZ)-injected (DM+MI group) or vehicle-injected mice (MI group) by ligating the left coronary artery. The ERK5-SUMOylation was increased in the DM+MI, but not in the MI group. ERK5-SUMOylation, the exacerbation of LV dysfunction, and the number of TUNEL-positive cells in DM+MI was significantly inhibited in CA-MEK5alpha-Tg mice. Of note, we could not detect any difference of cardiac function after MI in non-diabetic CA-MEK5alpha-Tg and non-transgenic littermate control mice. These results demonstrated that ERK5 transcriptional activity is subject to downregulation by diabetes-dependent SUMOylation, which resulted in a proapoptotic condition contributing to poor post-MI LV function.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18467627      PMCID: PMC2614366          DOI: 10.1161/CIRCRESAHA.107.168138

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  19 in total

Review 1.  Protein modification by SUMO.

Authors:  Erica S Johnson
Journal:  Annu Rev Biochem       Date:  2004       Impact factor: 23.643

2.  c-Src is required for oxidative stress-mediated activation of big mitogen-activated protein kinase 1.

Authors:  J i Abe; M Takahashi; M Ishida; J D Lee; B C Berk
Journal:  J Biol Chem       Date:  1997-08-15       Impact factor: 5.157

3.  Overexpression of the sarcoplasmic reticulum Ca(2+)-ATPase improves myocardial contractility in diabetic cardiomyopathy.

Authors:  Susanne U Trost; Darrell D Belke; Wolfgang F Bluhm; Markus Meyer; Eric Swanson; Wolfgang H Dillmann
Journal:  Diabetes       Date:  2002-04       Impact factor: 9.461

4.  Molecular cloning of mouse ERK5/BMK1 splice variants and characterization of ERK5 functional domains.

Authors:  C Yan; H Luo; J D Lee; J Abe ; B C Berk
Journal:  J Biol Chem       Date:  2001-01-03       Impact factor: 5.157

5.  BMK1/ERK5 regulates serum-induced early gene expression through transcription factor MEF2C.

Authors:  Y Kato; V V Kravchenko; R I Tapping; J Han; R J Ulevitch; J D Lee
Journal:  EMBO J       Date:  1997-12-01       Impact factor: 11.598

Review 6.  Regulation of cardiac remodeling by nitric oxide: focus on cardiac myocyte hypertrophy and apoptosis.

Authors:  Kai C Wollert; Helmut Drexler
Journal:  Heart Fail Rev       Date:  2002-10       Impact factor: 4.214

7.  Streptozotocin-induced hyperglycemia exacerbates left ventricular remodeling and failure after experimental myocardial infarction.

Authors:  Tetsuya Shiomi; Hiroyuki Tsutsui; Masaki Ikeuchi; Hidenori Matsusaka; Shunji Hayashidani; Nobuhiro Suematsu; Jing Wen; Toru Kubota; Akira Takeshita
Journal:  J Am Coll Cardiol       Date:  2003-07-02       Impact factor: 24.094

8.  Toll-like receptor-2 modulates ventricular remodeling after myocardial infarction.

Authors:  Tetsuro Shishido; Naoki Nozaki; Seiji Yamaguchi; Yoko Shibata; Joji Nitobe; Takuya Miyamoto; Hiroki Takahashi; Takanori Arimoto; Kunihiko Maeda; Mitsunori Yamakawa; Osamu Takeuchi; Shizuo Akira; Yasuchika Takeishi; Isao Kubota
Journal:  Circulation       Date:  2003-12-01       Impact factor: 29.690

9.  Extracellular signal-regulated kinase 5 SUMOylation antagonizes shear stress-induced antiinflammatory response and endothelial nitric oxide synthase expression in endothelial cells.

Authors:  Chang-Hoon Woo; Tetsuro Shishido; Carolyn McClain; Jae Hyang Lim; Jian-Dong Li; Jay Yang; Chen Yan; Jun-ichi Abe
Journal:  Circ Res       Date:  2008-01-24       Impact factor: 17.367

10.  The effect of diabetes on outcomes of patients with advanced heart failure in the BEST trial.

Authors:  Michael Domanski; Heidi Krause-Steinrauf; Prakash Deedwania; Dean Follmann; Jalal K Ghali; Edward Gilbert; Steven Haffner; Richard Katz; JoAnn Lindenfeld; Brian D Lowes; Wade Martin; Frank McGrew; Michael R Bristow
Journal:  J Am Coll Cardiol       Date:  2003-09-03       Impact factor: 24.094

View more
  39 in total

1.  Extracellular-regulated-kinase 5-mediated renal protection against ischemia-reperfusion injury.

Authors:  Tomoko Kawakami; Sang Won Park; Ryuji Kaku; Jay Yang
Journal:  Biochem Biophys Res Commun       Date:  2012-01-24       Impact factor: 3.575

Review 2.  Mitogen-activated protein kinase signaling in the heart: angels versus demons in a heart-breaking tale.

Authors:  Beth A Rose; Thomas Force; Yibin Wang
Journal:  Physiol Rev       Date:  2010-10       Impact factor: 37.312

3.  Novel role of C terminus of Hsc70-interacting protein (CHIP) ubiquitin ligase on inhibiting cardiac apoptosis and dysfunction via regulating ERK5-mediated degradation of inducible cAMP early repressor.

Authors:  Chang-Hoon Woo; Nhat-Tu Le; Tetsuro Shishido; Eugene Chang; Hakjoo Lee; Kyung-Sun Heo; Deanne M Mickelsen; Yan Lu; Carolyn McClain; Thomas Spangenberg; Chen Yan; Carlos A Molina; Jay Yang; Cam Patterson; Jun-ichi Abe
Journal:  FASEB J       Date:  2010-08-19       Impact factor: 5.191

Review 4.  Coordination of Cellular Localization-Dependent Effects of Sumoylation in Regulating Cardiovascular and Neurological Diseases.

Authors:  Jun-Ichi Abe; Uday G Sandhu; Nguyet Minh Hoang; Manoj Thangam; Raymundo A Quintana-Quezada; Keigi Fujiwara; Nhat Tu Le
Journal:  Adv Exp Med Biol       Date:  2017       Impact factor: 2.622

5.  Cyclic nucleotide phosphodiesterase 1A: a key regulator of cardiac fibroblast activation and extracellular matrix remodeling in the heart.

Authors:  Clint L Miller; Yujun Cai; Masayoshi Oikawa; Tamlyn Thomas; Wolfgang R Dostmann; Manuela Zaccolo; Keigi Fujiwara; Chen Yan
Journal:  Basic Res Cardiol       Date:  2011-10-20       Impact factor: 17.165

Review 6.  Oxidative stress response and Nrf2 signaling in aging.

Authors:  Hongqiao Zhang; Kelvin J A Davies; Henry Jay Forman
Journal:  Free Radic Biol Med       Date:  2015-06-09       Impact factor: 7.376

7.  ERK5 Contributes to VEGF Alteration in Diabetic Retinopathy.

Authors:  Yuexiu Wu; Yufeng Zuo; Rana Chakrabarti; Biao Feng; Shali Chen; Subrata Chakrabarti
Journal:  J Ophthalmol       Date:  2010-06-30       Impact factor: 1.909

8.  Diacylglycerol kinase α exacerbates cardiac injury after ischemia/reperfusion.

Authors:  Toshiki Sasaki; Tetsuro Shishido; Shinpei Kadowaki; Tatsuro Kitahara; Satoshi Suzuki; Shigehiko Katoh; Akira Funayama; Shunsuke Netsu; Tetsu Watanabe; Kaoru Goto; Yasuchika Takeishi; Isao Kubota
Journal:  Heart Vessels       Date:  2013-05-30       Impact factor: 2.037

Review 9.  SUMO--a post-translational modification with therapeutic potential?

Authors:  Chang-Hoon Woo; Jun-Ichi Abe
Journal:  Curr Opin Pharmacol       Date:  2010-01-14       Impact factor: 5.547

10.  SUMO modification of menin.

Authors:  Zi-Jie Feng; Buddha Gurung; Guang-Hui Jin; Xiao-Lu Yang; Xian-Xin Hua
Journal:  Am J Cancer Res       Date:  2013-01-18       Impact factor: 6.166

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.